PURPOSE: Rebeccamycin analog (NSC 655649) is active against a variety of both solid and nonsolid tumor cell lines. We performed a phase I trial to determine the maximum-tolerated dose (MTD) of rebeccamycin analog when given on a daily x 5 schedule repeated every 3 weeks, characterize the toxicity profile using this schedule, observe patients for antitumor response, and determine the pharmacokinetics of the agent and pharmacodynamic interactions. PATIENTS AND METHODS: Thirty assessable patients received a total of 153 cycles according to the following dose escalation schema: 60, 80, 106, 141, and 188 mg/m(2)/d x 5 days. RESULTS: Grade 2 phlebitis occurred in all patients before the use of central venous access, placed at dose level 4 and higher. Dose-limiting toxicity (DLT), grade 4 neutropenia, occurred at 188 mg/m(2)/d x 5 days in both previously treated and chemotherapy-naive patients. Pharmacokinetic analysis revealed a three-compartmental model of drug elimination and a long terminal half-life (154 +/- 55 hours). The percentage drop in absolute neutrophil count correlates with the area under the curve infinity. The presence of a second peak during the elimination phase as well as a high concentration of NSC 655649 in biliary fluid compared with the corresponding plasma measurement (one patient) is suggestive of enterohepatic circulation. Two partial responses, two minor responses, and six prolonged (> 6 months) cases of stable disease were observed. Of these, three patients with gallbladder cancer and one patient with cholangiocarcinoma experienced either a minor response or a significant period of freedom from progression. CONCLUSION: The recommended phase II dose for NSC 665649 on a daily x 5 every 3 weeks schedule is 141 and 165 mg/m(2)/d for patients with prior and no prior therapy, respectively, with DLT being neutropenia. During this phase I trial, encouraging antitumor activity was been observed.
PURPOSE:Rebeccamycin analog (NSC 655649) is active against a variety of both solid and nonsolid tumor cell lines. We performed a phase I trial to determine the maximum-tolerated dose (MTD) of rebeccamycin analog when given on a daily x 5 schedule repeated every 3 weeks, characterize the toxicity profile using this schedule, observe patients for antitumor response, and determine the pharmacokinetics of the agent and pharmacodynamic interactions. PATIENTS AND METHODS: Thirty assessable patients received a total of 153 cycles according to the following dose escalation schema: 60, 80, 106, 141, and 188 mg/m(2)/d x 5 days. RESULTS: Grade 2 phlebitis occurred in all patients before the use of central venous access, placed at dose level 4 and higher. Dose-limiting toxicity (DLT), grade 4 neutropenia, occurred at 188 mg/m(2)/d x 5 days in both previously treated and chemotherapy-naive patients. Pharmacokinetic analysis revealed a three-compartmental model of drug elimination and a long terminal half-life (154 +/- 55 hours). The percentage drop in absolute neutrophil count correlates with the area under the curve infinity. The presence of a second peak during the elimination phase as well as a high concentration of NSC 655649 in biliary fluid compared with the corresponding plasma measurement (one patient) is suggestive of enterohepatic circulation. Two partial responses, two minor responses, and six prolonged (> 6 months) cases of stable disease were observed. Of these, three patients with gallbladder cancer and one patient with cholangiocarcinoma experienced either a minor response or a significant period of freedom from progression. CONCLUSION: The recommended phase II dose for NSC 665649 on a daily x 5 every 3 weeks schedule is 141 and 165 mg/m(2)/d for patients with prior and no prior therapy, respectively, with DLT being neutropenia. During this phase I trial, encouraging antitumor activity was been observed.
Authors: Harold J Burstein; Beth Overmoyer; Rebecca Gelman; Paula Silverman; Jennifer Savoie; Kathryn Clarke; Leda Dumadag; Jerry Younger; Percy Ivy; Eric P Winer Journal: Invest New Drugs Date: 2006-09-13 Impact factor: 3.850
Authors: Rodrigo B Interiano; Amos H P Loh; Nathan Hinkle; Fazal N Wahid; Alpin D Malkan; Armita Bahrami; Jesse J Jenkins; Shenghua Mao; Jianrong Wu; Kimberly Proctor; Victor M Santana; Alberto S Pappo; Robert E Gold; Andrew M Davidoff Journal: Cancer Date: 2014-12-18 Impact factor: 6.860
Authors: Charles J Nock; Joanna M Brell; Joseph A Bokar; Matthew M Cooney; Brenda Cooper; Joseph Gibbons; Smitha Krishnamurthi; Sudhir Manda; Panayiotis Savvides; Scot C Remick; Percy Ivy; Afshin Dowlati Journal: Invest New Drugs Date: 2009-09-23 Impact factor: 3.850
Authors: Afshin Dowlati; James Posey; Ramesh K Ramanathan; Linda Rath; Pingfu Fu; Amitabh Chak; Smitha Krishnamurthi; Joanna Brell; Stephen Ingalls; Charles L Hoppel; Percy Ivy; Scot C Remick Journal: Cancer Chemother Pharmacol Date: 2009-04-28 Impact factor: 3.333
Authors: Robert W Robey; Tomasz Obrzut; Suneet Shukla; Orsolya Polgar; Sira Macalou; Julian C Bahr; Attilio Di Pietro; Suresh V Ambudkar; Susan E Bates Journal: Cancer Chemother Pharmacol Date: 2009-01-09 Impact factor: 3.333